Paragonix Technologies Launches New OPTION On-Demand Preservation Services Network

Paragonix Technologies announces the launch of its new OPTION On-Demand Preservation Services Network in the United States. OPTION is an around-the-clock rapid deployment service designed to better serve the transplant community and improve efficiencies in donor organ procurement and recovery.

The company reports the first phase of the OPTION program has launched, including the establishment of a nationwide forward deployment of distributed inventory at responsive depots to ensure transplant surgeons have access to advanced hypothermic preservation technologies.

Due to increased product demands, and the challenging logistics associated with recovering, preserving and transporting donor organs, regularly in only a few hours and often in the middle of the night, Paragonix Technologies is launching this just-in-time service to ensure 24/7 availability of Paragonix organ preservation products.

In addition, with a rise in “local procurement,” an increasingly common situation where a transplant team local to the donor recovers the organ(s) and sends them to the recipient hospital transplant team, the need has increased for distributed inventory and a more rapidly deployed product. A recent recovery in Alaska required the securing of a locally inventoried Paragonix organ preservation device in under a few hours, to support the transport of a donor organ to the east coast. By increasing access to regionally available inventory, Paragonix will support logistically challenging procurements and improve the efficiency of the organ donation system.

“We are proud to offer the OPTION in collaboration with top logistics providers across the country,” says Garrett Riddle, VP Manufacturing at Paragonix Technologies. “Whether it is an outreach from a U.S. transplant center or Organ Procurement Organization, our team is now able to rapidly deploy Paragonix devices to the site of organ donation 24/7/365.”
“The donation and transplant teams involved in donor organ procurements are working tirelessly around the clock to serve donor families and transplant recipients. While we have offered 24/7 clinical and technical support since market entry, we can now supercharge customer support with our OPTION program,” said Lisa Anderson, Ph.D., President & CEO at Paragonix Technologies, Inc. “This new offering will increase our coverage for any type of case that arises.”

OPTION is just the latest element in a strategy to provide advanced services to improve transplant efficiencies. Paragonix has already launched a digital platform to enhance transplant team coordination and data visibility. In future phases the company will be further expanding offerings to continue improve the efficiency and effectiveness of transplant services.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version